The cardiovascular system in idiopathic pulmonary fibrosis

Sy Giin Chong, Toyoshi Yanagihara, Martin R.J. Kolb

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The incidence and prevalence of ILDs, especially IPF, is on the rise. Despite improved clinical management, IPF still remains a challenging disease, especially with regard to its cardiovascular comorbidity. This chapter provides readers with recent updates regarding cardiovascular involvement in IPF. There is a significant association between CAD and IPF, and this may be due to a combination of common shared risk factors, hypoxia and oxidative stress. The mechanism behind the development of PH in IPF is incompletely understood; comparison with other ILDs may offer clarification. Importantly, arrhythmias are present in a significant portion of the daily activities of IPF patients, as well as post-lung transplant IPF patients. Antifibrotics such as pirfenidone and nintedanib are generally safe from the cardiac point of view. The impact of cardiovascular comorbidities on the survival of IPF patients is discussed before we explore the challenges faced in managing this vulnerable patient population.

Original languageEnglish
Pages (from-to)198-211
Number of pages14
JournalERS Monograph
Volume2020
Issue number9781849841191
DOIs
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'The cardiovascular system in idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this